ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2026
Reducing time-to-result in bloodstream infections: comparative evaluation of VITEK® REVEAL™ and QuickMIC® for rapid phenotypic antimicrobial susceptibility testing.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeBloodstream infections (BSI) require rapid and targeted antimicrobial therapy to improve clinical outcomes and reduce mortality. Conventional antimicrobial susceptibility testing (AST) requires 24-48 h to provide phenotypic susceptibility results and Minimum Inhibitory Concentration (MIC) values. In this study, we evaluated two rapid phenotypic AST systems, VITEK® REVEAL™ (bioMérieux, France) and QuickMIC® (Gradientech AB, Uppsala Science Park, Sweden), using the MicroScan WalkAway (Beckman Coulter, USA) system as reference method.
methods81 monomicrobial Gram-negative Positive Blood Cultures (PBC) were collected between November 2024 and September 2025 at AOU Città della Salute e della Scienza, including multidrug-resistant isolates and ESBL/carbapenemase producers. Performance was assessed by calculating Categorical Agreement (CA), Essential Agreement (EA), Very Major Errors (VME), Major Errors (ME), minor Errors (mE) and bias.
resultsVITEK® REVEAL™ demonstrated excellent overall performances, with CA and EA values of 96.8% and 97.5%, respectively. QuickMIC® showed high overall CA and EA (97.1% and 96.8%, respectively), but a higher proportion of invalid results (6.5%). Overall, both systems displayed better performances for Enterobacterales, whereas lower concordance and higher error rates were observed for P. aeruginosa, highlighting the challenge associated with this pathogen. Regarding Turn-Around-Time (TTR), QuickMIC® provided results significantly earlier than VITEK® REVEAL™ (mean 3.3 h vs 5.5 h), although it required more extensive manual preparation.
conclusionsOverall, both platforms proved to be reliable tools for rapid AST directly from PBC, with distinct advantages and limitations. Their integration into routine clinical workflows may support earlier targeted therapy and improve antimicrobial stewardship in the management of BSI.
Indexed as
Identifiers
42550394What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.